A patient aged 63 years, is diagnosed to have severe aplastic anemia. HLA compatible sibling is available. The best option of treatment is :
**Core Concept**
Severe aplastic anemia (SAA) is a life-threatening condition characterized by bone marrow failure, leading to pancytopenia. Treatment options for SAA include immunosuppressive therapy, bone marrow transplantation, and supportive care. The goal of treatment is to restore hematopoiesis and prevent complications.
**Why the Correct Answer is Right**
The correct answer, **Anti-thymocyte globulin followed by cyclosporine**, is the best option for treatment in this scenario. This approach involves using Anti-thymocyte globulin (ATG), an immunosuppressive agent, to deplete T-cells and promote hematopoiesis. Cyclosporine is then administered to maintain immunosuppression and prevent graft-versus-host disease (GVHD). This combination therapy has been shown to be effective in inducing remission in patients with SAA, particularly those with HLA-compatible siblings.
**Why Each Wrong Option is Incorrect**
**Option B:** A conventional bone marrow transplantation from the HLA identical sibling is not the best option initially, as it carries a higher risk of complications, including GVHD and transplant-related mortality. Immunosuppressive therapy is typically the first-line approach for SAA.
**Option C:** A non-myeloablative bone marrow transplantation from the HLA identical sibling may be considered in certain cases, but it is not the best option for this patient. Non-myeloablative conditioning regimens are generally used in older patients or those with significant comorbidities.
**Option D:** Cyclosporine alone is not sufficient to induce remission in SAA. While cyclosporine can be used as part of immunosuppressive therapy, it is typically used in combination with other agents, such as ATG, to achieve optimal results.
**Clinical Pearl / High-Yield Fact**
In patients with SAA, the use of ATG followed by cyclosporine has been shown to improve hematologic recovery and reduce the risk of relapse. This approach is particularly effective in patients with HLA-compatible siblings, making it an essential consideration in the management of SAA.
**✓ Correct Answer: A. Anti-thymocyte globulin followed by cyclosporine**